A STUDY OF SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES IN PARTICIPANTS WITH HEPATIC IMPAIRMENT AND NORMAL HEPATIC FUNCTION (FXS6837-I-102)
AN OPEN-LABEL, PARALLEL-GROUP CLINICAL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES FOLLOWING A SINGLE DOSE IN PARTICIPANTS WITH MILD AND MODERATE HEPATIC IMPAIRMENT AND PARTICIPANTS WITH NORMAL HEPATIC FUNCTION
This is a single-center, single-dose, parallel-group, open-label phase I clinical study to evaluate the safety, pharmacokinetics, and pharmacodynamics of FXS6837 between participants with mild and moderate hepatic impairment and participants with normal hepatic function
研究概览
详细说明
Approximately 24 participants with hepatic impairment and participants with normal hepatic function are planned to be enrolled into this study. Participants will undergo screening examinations from D-28 to D-1. Eligible participants will be admitted to the clinical study site on D-1. During the trial, participants will undergo laboratory tests, 12-lead ECG, vital sign observation, AE collection, and PK, PD, and plasma protein binding (PPB) sample collection.
研究类型
注册 (估计的)
阶段
- 阶段1
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Male or female, aged 18-70 years (both inclusive), at screening;
-
Weight ≥ 50 kg and ≤ 120.0 kg for males, weight ≥ 45 kg and ≤ 120.0 kg for females, and body mass index (BMI) 18.0-35.0 kg/m2 (both inclusive), at screening;
-
Subject is eligible to enter the study if:
- matched control subject: physical examination, vital signs, laboratory tests (hematology, serum chemistry, urinalysis, coagulation function, etc.), 12-lead ECG, abdomen ultrasound, and chest X-ray judged by the investigator to be normal or abnormal without clinical significance;
- Subject with mild or moderate hepatic impairment:Chronic hepatic impairment caused by primary liver diseases: this condition is defined as patients with a prior diagnosis of hepatic impairment whose liver function is assessed by the investigator to have been stable for ≥ 3 months on the basis of clinical manifestations, with Child-Pugh Class A/mild (5-6 points) or Class B/moderate (7-9 points).
Exclusion Criteria:
-
Patients with serious diseases of cardiovascular, respiratory, digestive, endocrine, renal, hematological, or neurological/psychiatric systems within 1 year prior to screening;
-
Positive T-SPOT test results during the screening period, considered to indicate active tuberculosis based on the participant's clinical symptoms, chest X-ray, and laboratory tests;
-
History of meningococcal infection, or history of meningococcal infection in first-degree relatives; Or confirmed history of infection with encapsulated microorganisms within 6 months prior to screening, including but not limited to Streptococcus pneumoniae, Klebsiella pneumoniae, and Haemophilus influenzae;
-
History of known or suspected immunodeficiency, hereditary or acquired complement deficiency; Or current use of immunosuppressants;
-
Pregnant or lactating women or those with positive pregnancy test results;
-
Subjects with hepatic impairment will not be eligible to participate in the study if any of the following exclusion criteria also apply:
- Drug-induced liver injury;
- History of liver transplantation;
- Presence of serious ascites or pleural effusion requiring puncture drainage;
- Hepatorenal syndrome;
- Diseases affecting biliary excretion, such as biliary cirrhosis, biliary obstruction, and cholestatic liver disease, within 3 months prior to screening;
- Serious portal hypertension rendering the patient unsuitable for participating in the study as assessed by the investigator;
- History of portosystemic shunt surgery, including transjugular intrahepatic portosystemic shunt;
- Current liver failure or complicated with Grade 2-4 hepatic encephalopathy;
- Suspected or confirmed liver cancer;
- Cirrhosis with complications such as esophageal or gastric variceal bleeding, spontaneous peritonitis, etc., that the investigator considers unsuitable for participation in the study, within 3 months prior to screening;
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Mild hepatic impairment
Arm 1:mild hepatic impairment, FXS6837 125mg orally once. |
Mild hepatic impairment, FXS6837 125mg orally once. |
|
实验性的:Moderate hepatic impairment
Arm 2: moderate hepatic impairment, FXS6837 125mg orally once. |
Mild hepatic impairment, FXS6837 125mg orally once. |
|
实验性的:Normal hepatic function
Arm 3: normal hepatic function FXS6837 125mg orally once. |
Mild hepatic impairment, FXS6837 125mg orally once. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Primary Pharmacokinetics(PK) parameter of FXS6837 in plasma:Cmax
大体时间:Up to Day 14
|
Maximum observed concentration (Cmax) |
Up to Day 14
|
|
Primary PK parameter of FXS6837 in plasma: AUC0-t
大体时间:Up to Day 14
|
Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) |
Up to Day 14
|
|
Primary PK parameter of FXS6837 in plasma: AUC0-∞
大体时间:Up to Day 14
|
area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) |
Up to Day 14
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Secondary PK parameter of FXS6837 in plasma: Tmax
大体时间:Up to Day 14
|
Time to reach maximum concentration(Tmax) |
Up to Day 14
|
|
Secondary PK parameter of FXS6837 in plasma: t1/2
大体时间:Up to Day 14
|
Half-life (t1/2) |
Up to Day 14
|
|
Secondary PK parameter of FXS6837 in plasma: CL/F
大体时间:Up to Day 14
|
Apparent total plasma clearance (CL/F) |
Up to Day 14
|
|
Secondary PK parameter of FXS6837 in plasma: Vz/F
大体时间:Up to Day 14
|
Apparent terminal volume of distribution (Vz/F) |
Up to Day 14
|
|
PK parameter of unbound FXS6837 in plasma: Cmax,u
大体时间:Up to Day 14
|
Maximum unbound concentration (Cmax, u) |
Up to Day 14
|
|
PK parameter of unbound FXS6837 in plasma: AUC0-t, u
大体时间:Up to Day 14
|
Area under the unbound plasma concentration-time curve from time 0 to time t (AUC0-t, u) |
Up to Day 14
|
|
PK parameter of unbound FXS6837 in plasma: AUC0-∞, u
大体时间:Up to Day 14
|
Area under the unbound plasma concentration-time curve from time 0 to infinity (AUC0-∞, u) |
Up to Day 14
|
|
Incidence and severity of AE and SAE
大体时间:Up to Day 14
|
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs), including abnormalities in clinical symptoms and vital signs, physical examination, 12-lead electrocardiogram (ECG), and laboratory tests |
Up to Day 14
|
|
Pharmacodynamics indicator of FXS6837. Change from baseline in peripheral blood complement Alternative Pathway activity
大体时间:Up to Day 5
|
Complement alternative pathway (AP) activity in peripheral blood.Complement alternative pathway (AP) activity will be measured in peripheral blood. Absolute change and percentage change from baseline to Day 5 will be assessed. |
Up to Day 5
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- FXS6837-I-102
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.